MicuRx begins Phase I trial of MRX-4 against Gram-positive bacteria

US-based biopharmaceutical company MicuRx has begun its Phase I clinical trial of MRX-4, for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news